The Latest Cardiac and Vascular News
Guide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced […]
This is the first study to investigate the safety and tolerability of NR in a randomized, placebo-controlled trial of patients with heart failure, marking a milestone for future clinical research LOS ANGELES–(BUSINESS WIRE)–ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of […]
The latest prespecified and post hoc sub-analysis of the landmark REDUCE-IT® study, published today in the Journal of the American College of Cardiology (JACC), demonstrated that VASCEPA® (icosapent ethyl) significantly reduces the total ischemic event risk of cardiovascular death, stroke, myocardial infarction (heart attack), coronary revascularization, or hospitalization for unstable angina by 35% […]
New editorial published in the Journal of the American College of Cardiology compares cardiovascular disease prevention treatments MANHASSET, N.Y.–(BUSINESS WIRE)–Patients most likely to benefit from intensive systolic blood pressure treatment (SBP) versus standard treatment to reduce cardiovascular disease (CVD) may also be at risk for adverse events (AE). In an […]
A study published online first in the JACC: Cardiovascular Interventions found that Penumbra, Inc.’s Indigo Aspiration System met its predefined safety and efficacy endpoints for the treatment of pulmonary embolism (PE) in the EXTRACT-PE study. Specific results include a significant mean reduction in right ventricular (RV)/left ventricular (LV) ratio of […]
VANCOUVER, Jan. 23, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Journal of the American College of Cardiology: […]
